Overview

A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Primary - To investigate the safety and tolerability of LCB01-0371 after a single oral dose Secondary - To investigate the pharmacokinetic characteristics of LCB01-0371 after a single oral dose - To investigate the safety of LCB01-0371 after a single oral dose
Phase:
Phase 1
Details
Lead Sponsor:
LegoChem Biosciences, Inc
Treatments:
Delpazolid
Linezolid